Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dextrose, 5% in Water · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Infusion #1 (Week 0)Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min) ; Infusion #2 (Week 3-4)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min) |
| Group 2 | EXPERIMENTAL | Infusion #1 (Week 0)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min); Infusion #2 Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min) |
| Name | Type | Description |
|---|---|---|
| Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified | DRUG | - |
| Dextrose, 5% in Water | DRUG | - |
Inclusion Criteria: * Confirmed diagnosis of primary immune deficiency and medical records available for retrospective review for at least 3 months prior to entry into the trial * Signed an informed consent written informed consent prior to initiation of any study related procedures * Receiving reg...
Dextrose, 5% in Water is used in the treatment of Immunologic Deficiency Syndrome, a rare disease. It is a small molecule being developed by Grifols, S.A. The drug is currently in Phase 3 clinical development for this indication.
Dextrose, 5% in Water is being developed by Grifols, S.A., a company listed on the stock exchange under the ticker GRFS. The drug is in Phase 3 clinical development for Immunologic Deficiency Syndrome.
Dextrose, 5% in Water is in Phase 3 clinical development. It is an investigational drug being studied for the treatment of Immunologic Deficiency Syndrome, a rare disease. The drug has not been approved and remains in clinical trials.
Dextrose, 5% in Water is associated with clinical trial NCT00220766, titled "Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients." This Phase 3 trial has been completed and enrolled 100 participants in the United States and Canada.
In clinical trial NCT00220766, Dextrose, 5% in Water is studied in patients with Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, and Common Variable Immunodeficiency. The trial enrolled adults aged 18 years and older.